 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | NV-CoV-2 / NanoViricides
Journal: Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19. (Pubmed Central) - Dec 31, 2022
Secondly, RDV is protected from plasma-mediated degradation in transit. All together, NV-CoV-2-R is the safest and efficient regimen against COVID-19.
- ||| NV-CoV-2 / NanoViricides
$NNVC NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage https://t.co/TRkjMJD7DE #coronavirus (Twitter) - Nov 15, 2022
- || NV-CoV-2 / NanoViricides
Review, Journal: Mechanism of Antiviral Activities of Nanoviricide's Platform Technology based Biopolymer (NV-CoV-2). (Pubmed Central) - Jun 4, 2022
In this study, RDV was encapsulated and protected from serum-mediated degradation in vivo. As a result, RDV was available for a longer period of time to interact with RNA polymerase and inhibit.
- ||| NV-CoV-2 / NanoViricides
$NNVC NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program https://t.co/32aABn7lVw #coronavirus (Twitter) - Apr 25, 2022